Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Atrinsic Inc. (PTIX : NSDQ)
 
 • Company Description   
Protagenic Therapeutics, Inc. is a biotechnology company. It focused on the discovery, research and development of novel and naturally occurring human brain hormones for the treatment of anxiety and depression based mood disorders. Protagenic Therapeutics, Inc., formerly known as Atrinsic, Inc., is based in New York, United States.

Number of Employees: 2

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.76 Daily Weekly Monthly
20 Day Moving Average: 48,768 shares
Shares Outstanding: 17.28 (millions)
Market Capitalization: $13.17 (millions)
Beta: -0.07
52 Week High: $4.19
52 Week Low: $0.58
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -15.22% -4.52%
12 Week -17.35% -9.14%
Year To Date -44.98% -33.30%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
149 FIFTH AVENUE SUITE 500
-
NEW YORK,NY 10010
USA
ph: 212-994-8200
fax: 603-761-6223
alex.arrow@protagenic.com http://www.protagenic.com
 
 • General Corporate Information   
Officers
Garo H. Armen - Chairman
Andrew Slee - Chief Operating Officer
Alexander K. Arrow - Chief Financial Officer
Khalil Barrage - Director
Josh Silverman - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 74365N103
SIC: 7389
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/21
Next Expected EPS Date: 05/23/22
Share - Related Items
Shares Outstanding: 17.28
Most Recent Split Date: 7.00 (0.01:1)
Beta: -0.07
Market Capitalization: $13.17 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 05/23/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.51
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 50.00%
vs. Previous Quarter: 54.55%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -46.99
12/31/21 - -62.11
09/30/21 - -92.17
ROA
03/31/22 - -41.99
12/31/21 - -51.73
09/30/21 - -67.05
Current Ratio
03/31/22 - 12.50
12/31/21 - 13.82
09/30/21 - 16.10
Quick Ratio
03/31/22 - -
12/31/21 - 13.83
09/30/21 - 16.10
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 0.50
12/31/21 - 0.59
09/30/21 - 0.62
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.03
12/31/21 - 0.03
09/30/21 - 0.05
Debt-to-Capital
03/31/22 - 3.27
12/31/21 - 3.10
09/30/21 - 5.14
 

Powered by Zacks Investment Research ©